New Alliance Capital
China's Lynk Pharmaceutical increases Series C to $44m
China-based drug developer Lynk Pharmaceuticals has closed a second tranche of Series C funding, taking the overall size of the round to CNY 322m (USD 44m).
LAV leads $50m Series B for China's Lynk Pharma
Lilly Asia Ventures (LAV) has led a $50 million Series B round for Lynk Pharmaceuticals, a China-based drug developer that focuses on small-molecule treatments for autoimmune disease, inflammation, and cancer.